Merck wins Japan approval for subcutaneous Keytruda across uses
Japan’s MHLW approved Merck’s KEYTRUDA QLEX (subcutaneous pembrolizumab combo) for all existing Keytruda indications in Japan, enabling 1–2 minute injections.
Japan’s MHLW approved Merck’s KEYTRUDA QLEX, a subcutaneous pembrolizumab combination, for all existing Keytruda indications in Japan. The approval allows 1—2 minute injections.